<DOC>
	<DOCNO>NCT00186966</DOCNO>
	<brief_summary>This international multicenter open label randomize phase III trial child relapse refractory acute myeloid leukemia ( AML ) disease . The main purpose study determine efficacy toxicity liposomal daunorubicin add fludarabine , ara-C G-CSF ( FLAG ) child relapse refractory AML .</brief_summary>
	<brief_title>Treatment Children Adolescents With Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>Secondary objective trial : - To determine toxicity liposomal daunorubicin add FLAG , term mucosal toxicity , bone marrow aplasia , short- long-term cardiotoxicity side effect compare patient treated FLAG . - To determine long-term clinical outcome prospectively large group child refractory relapse acute myeloid leukemia . - To determine change minimal residual disease time , prognostic significance minimal residual disease determine various time-points . - To determine relation vitro cellular drug resistance clinical cell biological feature , minimal residual disease clinical outcome patient group - To determine pharmacokinetics liposomal daunorubicin relation toxicity efficacy Reinduction treatment do 2 course combination chemotherapy , FLAG ( fludarabine , ara-C G-CSF ) course standard treatment . In first course randomisation liposomal daunorubicin ( DaunoXomeÂ® ) add . The second course always concern FLAG . If patient &gt; 20 % blast bone marrow 1st course , complete remission ( CR ) 2nd course , go protocol . Patients CR reinduction treatment immediately proceed stem cell transplantation . Consolidation chemotherapy give SCT delay . A 3rd course intensive chemotherapy ( VP16 continuous infusion cytarabine ) general recommendation . In selected patient , low intensity consolidation may prefer , schedule describe well . The type SCT base risk-group . Preferably , match sibling donor ( MSD ) SCT perform . If MSD available patient candidate match unrelated donor ( MUD ) SCT . If MUD also available , patient primary refractory disease , early relapse ( within 1 year diagnosis ) , great equal 2nd relapse , candidate experimental haplo-identical donor ( HID ) SCT view dismal prognosis . However , patient late relapse ( &gt; 1 year initial diagnosis ) good prognosis offer autologous SCT MSD MUD SCT possible . Only case autologous SCT , maintenance treatment and/or adjuvant immunotherapy could consider .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Children adolescents less eighteen year age start chemotherapy . Subject one following : Primary refractory AML , first relapse AML , second subsequent relapse AML previously treat accord particular protocol Subjects combine relapse , isolate extramedullary relapse , bone marrow relapse eligible , also randomization . Symptomatic cardiac dysfunction . Inadequate performance score . Any organ dysfunction interfere administration therapy . FAB type M3</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>